文献速递外周动脉疾病

紫杉醇涂层外周动脉器械与慢性肢体威胁性缺血患者总生存和保肢改善相关

Paclitaxel-coated peripheral arterial devices are associated with improved overall survival and limb salvage in patients with chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2021-06-06

本研究回顾性分析了983例接受股腘动脉介入治疗的慢性肢体威胁性缺血(CLTI)患者,比较使用与未使用紫杉醇(PTX)涂层器械的长期结局。中位随访4年,PTX组总生存率、无截肢生存率、免于大截肢率和免于靶血管血运重建率均显著优于非PTX组,多因素Cox回归证实PTX治疗与上述结局改善独立相关。

要点

  • 在CLTI患者中,PTX涂层器械与4年总生存率、无截肢生存率、免于大截肢率和免于靶血管血运重建率改善相关。
  • PTX涂层器械可能对表现为CLTI的患者尤其有益。

核心结论

  • 在CLTI患者中,使用PTX涂层器械治疗与4年随访期间总生存、无截肢生存、免于大截肢和免于靶血管血运重建的改善相关。

研究设计与样本

  • 回顾性队列研究,纳入2011年至2019年间接受股腘动脉血管成形术、斑块旋切术、支架植入或联合治疗的983例CLTI患者。
  • 574例(58.5%)接受PTX涂层器械治疗,409例(41.6%)未接受PTX涂层器械治疗。
  • 采用Kaplan-Meier生存分析和多因素Cox回归分析比较两组结局。

主要发现

  • 多因素Cox回归分析显示,PTX治疗与总生存、无截肢生存、免于大截肢和免于靶血管血运重建的改善相关。

临床怎么用

  • 对于表现为CLTI的股腘动脉病变患者,可考虑使用PTX涂层器械以改善长期生存和保肢结局。

局限性

  • 本研究为回顾性设计,可能存在选择偏倚和未测量的混杂因素。
  • 非PTX组男性比例更高(56.2% vs 49.7%)、透析依赖比例更高(19.6% vs 14.3%)、平均肌酐更高(2.3 vs 1.8 mg/dL)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Paclitaxel (PTX)-coated peripheral arterial devices have been shown to decrease femoropopliteal artery restenosis and the need for reintervention compared with non-PTX-coated devices. The data regarding PTX efficacy and safety come from randomized controlled trials that almost exclusively enrolled patients with claudication. The outcomes of PTX treatment in patients who present with chronic limb-threatening ischemia (CLTI) are unknown. This study compares long-term outcomes in patients with CLTI treated with and without PTX. METHODS: We retrospectively reviewed 983 patients with CLTI treated with femoropopliteal artery angioplasty, atherectomy, stent, or combination between 2011 and 2019. Procedures were performed with additional proximal or distal tibial interventions as needed. Kaplan-Meier survival analysis and multivariable Cox-regression analysis compared overall survival (OS), amputation-free survival (AFS), freedom from major amputation (ff-MA), and freedom from target vessel revascularization (ff-TVR) between patients treated with and without PTX. RESULTS: Demographics, comorbidities, and Rutherford class were similar between 574 PTX (58.5%) and 409 non-PTX (41.6%) patients except that non-PTX patients were more likely to be male (56.2% vs 49.7%), dialysis dependent (19.6% vs 14.3%), and have higher average creatinine (2.3 vs 1.8 mg/dL). Through 4-year follow-up, the PTX group demonstrated a significant increase in OS (56.2% vs 43.9%, P = .013), AFS (52.6% vs 36.1%, P < .0001), ff-MA (87.4% vs 78.7%, P = .0007), and ff-TVR (77.6% vs 70.6%, P = .012). Multivariable Cox-regression analysis demonstrated that PTX treatment was associated with improved OS, AFS, ff-MA, and ff-TVR. CONCLUSIONS: In patients with CLTI, treatment with a PTX-coated device is associated with improved OS, AFS, ff-MA, and ff-TVR through 4-year follow-up. PTX-coated devices may be especially beneficial in patients who present with CLTI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kumins NH, King AH, Ambani RN, et al. Paclitaxel-coated peripheral arterial devices are associated with improved overall survival and limb salvage in patients with chronic limb-threatening ischemia. J Vasc Surg. 2021. PMID: 34090989. doi:10.1016/j.jvs.2021.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。